Mechanisms of receptor tyrosine kinase activation in cancer

Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

(2018) Jean-Charles Soria et al.   NEW ENGLAND JOURNAL OF MEDICINE

Novel GOPC(FIG)-ROS1 fusion in a pediatric high-grade glioma survivor

(2017) Erin N. Kiehna et al.   Journal of Neurosurgery-Pediatrics

Molecular breakdown: a comprehensive view of anaplastic lymphoma kinase (ALK )- rearranged non-small cell lung cancer

(2017) Ka-Won Noh et al.   JOURNAL OF PATHOLOGY

HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo- and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib

(2017) Sai-Hong Ignatius Ou et al.   Journal of Thoracic Oncology

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

(2017) Gunter von Minckwitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Detection of anALKFusion in Colorectal Carcinoma by Hybrid Capture‐Based Assay of Circulating Tumor DNA

(2017) Andrea Z. Lai et al.   ONCOLOGIST

Therapeutic Potential of Afatinib for Cancers withERBB2(HER2) Transmembrane Domain Mutations G660D and V659E

(2017) Hiromasa Yamamoto et al.   ONCOLOGIST

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)

(2017) Alexander Drilon et al.   Cancer Discovery

A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion–Positive Solid Tumors

(2017) Alexander Drilon et al.   Cancer Discovery

Prognostic value of ERBB4 expression in patients with triple negative breast cancer

(2016) Ji-Yeon Kim et al.   BMC CANCER

Impact of the physical microenvironment on tumor progression and metastasis

(2016) Fabian Spill et al.   CURRENT OPINION IN BIOTECHNOLOGY

ROS1fusions in cancer: a review

(2016) Arnaud Uguen et al.   Future Oncology

Cabozantinib in patients with advanced RET -rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial

(2016) Alexander Drilon et al.   LANCET ONCOLOGY

Double Trouble: Kinase domain duplication as a new path to drug resistance

(2016) Hsin-Yi Chen et al.   Pigment Cell & Melanoma Research

MicroRNAs: Non-coding fine tuners of receptor tyrosine kinase signalling in cancer

(2016) Sara Donzelli et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

EGFR Fusions as Novel Therapeutic Targets in Lung Cancer

(2016) K. Konduri et al.   Cancer Discovery

Identification ofBRAFKinase Domain Duplications Across Multiple Tumor Types and Response to RAF Inhibitor Therapy

(2016) Samuel J. Klempner et al.   JAMA Oncology

The Receptor Tyrosine Kinase AXL in Cancer Progression

(2016) Erinn Rankin et al.   Cancers

A Detailed Clinicopathologic Study of ALK-translocated Papillary Thyroid Carcinoma

(2015) Angela Chou et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing

(2015) T. Helsten et al.   CLINICAL CANCER RESEARCH

Fibroblast growth factor receptor (FGFR) gene amplifications are rare events in bladder cancer

(2015) Anna Fischbach et al.   HISTOPATHOLOGY

Receptor tyrosine kinase mutations in developmental syndromes and cancer: two sides of the same coin

(2015) Laura M. McDonell et al.   HUMAN MOLECULAR GENETICS

Novel ALK inhibitors in clinical use and development

(2015) Chaitanya Iragavarapu et al.   Journal of Hematology & Oncology

RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK–positive lung cancer

(2015) Gorjan Hrustanovic et al.   NATURE MEDICINE

Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer

(2015)   NEW ENGLAND JOURNAL OF MEDICINE

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

(2015) Pasi A. Jänne et al.   NEW ENGLAND JOURNAL OF MEDICINE

EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib

(2015) J.-N. Gallant et al.   Cancer Discovery

NF-κB-Activating Complex Engaged in Response to EGFR Oncogene Inhibition Drives Tumor Cell Survival and Residual Disease in Lung Cancer

(2015) Collin M. Blakely et al.   Cell Reports

C-Kit and Its Ligand Stem Cell Factor: Potential Contribution to Prostate Cancer Bone Metastasis

(2015) Christoph Wiesner et al.   NEOPLASIA

PTEN

(2014) Carolyn A. Worby et al.   Annual Review of Biochemistry

Prognostic relevance of receptor tyrosine kinase expression in breast cancer: A meta-analysis

(2014) Arnoud J. Templeton et al.   CANCER TREATMENT REVIEWS

Multiple receptor tyrosine kinases converge on microRNA-134 to control KRAS, STAT5B and glioblastoma

(2014) Y Zhang et al.   CELL DEATH AND DIFFERENTIATION

PDGF/PDGFR Signaling and Targeting in Cancer Growth and Progression: Focus on Tumor Microenvironment and Cancer-associated Fibroblasts

(2014) Chrisostomi Gialeli et al.   CURRENT PHARMACEUTICAL DESIGN

Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor

(2014) M. Raymond V. Finlay et al.   JOURNAL OF MEDICINAL CHEMISTRY

Comprehensive molecular profiling of lung adenocarcinoma

(2014) Eric A. Collisson et al.   NATURE

Oncogenic Alterations in ERBB2/HER2 Represent Potential Therapeutic Targets Across Tumors From Diverse Anatomic Sites of Origin

(2014) J. Chmielecki et al.   ONCOLOGIST

The landscape of kinase fusions in cancer

(2014) Nicolas Stransky et al.   Nature Communications

Kinase fusions are frequent in Spitz tumours and spitzoid melanomas

(2014) Thomas Wiesner et al.   Nature Communications

Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor-Resistant EGFR-Mutant Lung Cancer with and without T790M Mutations

(2014) Y. Y. Janjigian et al.   Cancer Discovery

Inflammatory Myofibroblastic Tumors Harbor Multiple Potentially Actionable Kinase Fusions

(2014) C. M. Lovly et al.   Cancer Discovery

Blockage of a miR-21/EGFR regulatory feedback loop augments anti-EGFR therapy in glioblastomas

(2013) Kai-liang Zhang et al.   CANCER LETTERS

The Somatic Genomic Landscape of Glioblastoma

(2013) Cameron W. Brennan et al.   CELL

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

(2013) H. A. Yu et al.   CLINICAL CANCER RESEARCH

MicroRNA Signature in Metastatic Colorectal Cancer Patients Treated With Anti-EGFR Monoclonal Antibodies

(2013) Federico Cappuzzo et al.   Clinical Colorectal Cancer

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations

(2013) Lecia V. Sequist et al.   JOURNAL OF CLINICAL ONCOLOGY

Novel Germline Mutation in the Transmembrane Domain of HER2 in Familial Lung Adenocarcinomas

(2013) Hiromasa Yamamoto et al.   JNCI-Journal of the National Cancer Institute

RET Rearrangements in Lung Adenocarcinoma and Radiation

(2013) Sanja Dacic et al.   Journal of Thoracic Oncology

MET overexpression assessed by new interpretation method predicts gene amplification and poor survival in advanced gastric carcinomas

(2013) Sang Y Ha et al.   MODERN PATHOLOGY

Overexpression of EGFR in Head and Neck Squamous Cell Carcinoma Is Associated with Inactivation of SH3GL2 and CDC25A Genes

(2013) Guru Prasad Maiti et al.   PLoS One

miR-219-5p Inhibits Receptor Tyrosine Kinase Pathway by Targeting EGFR in Glioblastoma

(2013) Soumya Alige Mahabala Rao et al.   PLoS One

Mechanism for activation of mutated epidermal growth factor receptors in lung cancer

(2013) M. Red Brewer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cancer Genome Landscapes

(2013) B. Vogelstein et al.   SCIENCE

Identification of Targetable FGFR Gene Fusions in Diverse Cancers

(2013) Yi-Mi Wu et al.   Cancer Discovery

Response to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas

(2013) Alexander Drilon et al.   Cancer Discovery

Clinical Response to a Lapatinib-Based Therapy for a Li-Fraumeni Syndrome Patient with a Novel HER2V659E Mutation

(2013) V. Serra et al.   Cancer Discovery

Identification of Anaplastic Lymphoma Kinase as a Potential Therapeutic Target in Ovarian Cancer

(2012) H. Ren et al.   CANCER RESEARCH

Tumor endothelial markers as a target in cancer

(2012) Domenico Ribatti et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

MicroRNA-10a is involved in the metastatic process by regulating Eph tyrosine kinase receptor A4-Mediated epithelial-mesenchymal transition and adhesion in hepatoma cells*

(2012) Yan Yan et al.   HEPATOLOGY

Frequent Gene Amplification Predicts Poor Prognosis in Gastric Cancer

(2012) Jing Shi et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

RETFusions Define a Unique Molecular and Clinicopathologic Subtype of Non–Small-Cell Lung Cancer

(2012) Rui Wang et al.   JOURNAL OF CLINICAL ONCOLOGY

ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers

(2012) Kristin Bergethon et al.   JOURNAL OF CLINICAL ONCOLOGY

BRAFDuplications and MAPK Pathway Activation Are Frequent in Gliomas of the Optic Nerve Proper

(2012) Fausto J. Rodriguez et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

(2012) Rafael Rosell et al.   LANCET ONCOLOGY

Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies

(2012) Doron Lipson et al.   NATURE MEDICINE

RET, ROS1 and ALK fusions in lung cancer

(2012) Kengo Takeuchi et al.   NATURE MEDICINE

Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia

(2012) Alex Kentsis et al.   NATURE MEDICINE

Gene duplication as a mechanism of genomic adaptation to a changing environment

(2012) F. A. Kondrashov   PROCEEDINGS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES

Differential Sensitivity of Glioma- versus Lung Cancer–Specific EGFR Mutations to EGFR Kinase Inhibitors

(2012) Igor Vivanco et al.   Cancer Discovery

Evaluation of HER2 Protein Expression in Gastric Carcinomas: Comparative Analysis of 1414 Cases of Whole-Tissue Sections and 595 Cases of Tissue Microarrays

(2011) Kab Choong Kim et al.   ANNALS OF SURGICAL ONCOLOGY

A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors

(2011) T. Sasaki et al.   CANCER RESEARCH

Activation of Multiple Proto-oncogenic Tyrosine Kinases in Breast Cancer via Loss of the PTPN12 Phosphatase

(2011) Tingting Sun et al.   CELL

A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing

(2011) Y. S. Ju et al.   GENOME RESEARCH

KIT as a Therapeutic Target in Metastatic Melanoma

(2011) Richard D. Carvajal   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Tyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies

(2011) Sandrine Medves et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

(2011) Caicun Zhou et al.   LANCET ONCOLOGY

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

(2011) Poulikos I. Poulikakos et al.   NATURE

Mechanistic insights into the activation of oncogenic forms of EGF receptor

(2011) Zhihong Wang et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Amplification of the PDGFRA, KIT and KDR genes in glioblastoma: a population-based study

(2011) Sumihito Nobusawa et al.   NEUROPATHOLOGY

Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer

(2011) G Mudduluru et al.   ONCOGENE

Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer

(2011) Amit Dutt et al.   PLoS One

MiR-145 inhibits cell proliferation of human lung adenocarcinoma by targeting EGFR and NUDT1

(2011) William CS Cho et al.   RNA Biology

Mechanisms of chromosomal rearrangement in the human genome

(2010) Albert G Tsai et al.   BMC GENOMICS

Cell Signaling by Receptor Tyrosine Kinases

(2010) Mark A. Lemmon et al.   CELL

Docking proteins

(2010) Tilman Brummer et al.   FEBS Journal

PDGFRA rearrangement leading to hyper-eosinophilia, T-lymphoblastic lymphoma, myeloproliferative neoplasm and precursor B-cell acute lymphoblastic leukemia

(2010) Q Huang et al.   LEUKEMIA

New pattern of EGFR amplification in glioblastoma and the relationship of gene copy number with gene expression profile

(2010) Concha Lopez-Gines et al.   MODERN PATHOLOGY

Spatial control of EGF receptor activation by reversible dimerization on living cells

(2010) Inhee Chung et al.   NATURE

Crizotinib inALK-Rearranged Inflammatory Myofibroblastic Tumor

(2010) James E. Butrynski et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

(2010) Makoto Maemondo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

(2010) Eunice L. Kwak et al.   NEW ENGLAND JOURNAL OF MEDICINE

Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1α in non-small cell lung cancer cells

(2010) L Xu et al.   ONCOGENE

EML4-ALK Rearrangement in Non-Small Cell Lung Cancer and Non-Tumor Lung Tissues

(2009) Maria Paola Martelli et al.   AMERICAN JOURNAL OF PATHOLOGY

Lung Adenocarcinoma with EGFR Amplification Has Distinct Clinicopathologic and Molecular Features in Never-Smokers

(2009) L. M. Sholl et al.   CANCER RESEARCH

Mechanism for Activation of the EGF Receptor Catalytic Domain by the Juxtamembrane Segment

(2009) Natalia Jura et al.   CELL

Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis

(2009) Cristina Rodríguez-Antona et al.   ENDOCRINE-RELATED CANCER

Phase II Trial of Sorafenib in Metastatic Thyroid Cancer

(2009) Richard T. Kloos et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034

(2009) Martin J. van den Bent et al.   JOURNAL OF CLINICAL ONCOLOGY

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial

(2009) Robert Pirker et al.   LANCET

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

(2009) Tetsuya Mitsudomi et al.   LANCET ONCOLOGY

The Juxtamembrane Region of the EGF Receptor Functions as an Activation Domain

(2009) Monica Red Brewer et al.   MOLECULAR CELL

Kinase mutations in human disease: interpreting genotype–phenotype relationships

(2009) Piya Lahiry et al.   NATURE REVIEWS GENETICS

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer

(2009) F R Hirsch et al.   ONCOGENE

The Quest for the 1p36 Tumor Suppressor

(2008) A. Bagchi et al.   CANCER RESEARCH

Transcription-Dependent Epidermal Growth Factor Receptor Activation by Hepatocyte Growth Factor

(2008) T. E. Reznik et al.   MOLECULAR CANCER RESEARCH

Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

(2008) Jan B. Vermorken et al.   NEW ENGLAND JOURNAL OF MEDICINE

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

(2008) D Li et al.   ONCOGENE